Michael A. Curran, Ph.D.
Areas of Research
Despite the success of immunotherapy in melanoma, many immunologically “cold” tumors, such as prostate and pancreatic cancer, fail to respond to checkpoint blockade. Research in the Curran Laboratory focuses on discovering mechanisms by which these immune-resistant cancers evade the host T cell response and resist checkpoint antibody therapy. Companion translational studies investigate immunologic and metabolic interventions designed to reverse microenvironmental immune suppression and re-sensitize these cancers to host immunity.
Meet the Team
September 2018, from left to right: Anu Srinivasamani, Priya Jayaprakash, Ravaen Slay, Akash Boda, Casey Ager, Mike Curran, Meghan Dean, Gen Hartley, Alex Chen, Rishika Prasad, Arthur Liu, Brittany Charleton